Company profile
Bio Essence Corporation
OTC: BIOE · Healthcare · Drug Manufacturers - Specialty & Generic
#806 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
52DFH 72DQ 23GM 65SS 23
v0.1 · 65/100 weight · provisional
↑ operating margin, return on assets · ↓ listing tenure, balance-sheet leverage
Methodology →Revenue TTM
$2.9M
Rev growth YoY (TTM)
+416.6%
Net income (FY)
$896.2k
Employees
4
as of 2026-08-22
Market cap
$9.9M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.9M$1.9M2025
Net income$896.2k$896.2k2025
Operating income$900.0k$900.0k2025
Total assets$422.5k$422.5k2025
Liabilities$2.5M$2.5M2025
Equity-$2.1M-$2.1M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY23
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Bio Essence Corporation’s revenue?
Bio Essence Corporation booked $1.9M in FY2025 revenue, growing 486% year over year — faster than 94% of Healthcare companies we track, at a 47.2% net margin.
Peers · Healthcare
Anteris Technologies Global Corp.32DLongevity Health Holdings Inc.22DVeltex Corporation50DResonate Blends, Inc.——Vycor Medical, Inc.56CPharmaCielo Ltd.40DNeighbors
Orange →Key facts
CEOYin Yan
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersIrvine, CA
ExchangeOTC: BIOE
Employees4
IPO date2022-12-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.